Lv1
30 积分 2022-07-31 加入
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
20天前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
1个月前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
1个月前
已完结
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
3个月前
已完结
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
3个月前
已完结
肿瘤免疫治疗相关肝损伤的研究进展
5个月前
已完结
肿瘤免疫治疗相关肝损伤的研究进展
6个月前
已完结
Checkpoint inhibitor hepatotoxicity: pathogenesis and management
6个月前
已完结
Immune checkpoints in the tumor microenvironment
6个月前
已完结
The multiple roles of LDH in cancer
6个月前
已完结
皖公网安备34019202002308
